{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000017","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.149673+00:00","generated_at":"2026-06-18T11:47:00.587137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Entrada reports FY2022 net loss $94.6M; Vertex deal adds $224M upfront, extends cash into 2H 2025","bullets":["Net loss $24.6M Q4, $94.6M FY2022; R&D expenses $15.7M Q4, $66.6M FY2022.","Cash, equivalents & securities $188.7M at Dec 31, 2022; runway extended into 2H 2025 after Vertex deal.","Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; up to $485M milestones plus royalties.","FDA clinical hold on ENTR-601-44 IND; company working to resolve, aiming for healthy volunteer trial in 2023.","Selected ENTR-601-45 for Duchenne exon 45 skipping; IND planned for Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000017","json":"https://secwatch.observer/filing/0001689375-23-000017.json","markdown":"https://secwatch.observer/filing/0001689375-23-000017.md","text":"https://secwatch.observer/filing/0001689375-23-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/0001689375-23-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/trda-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:47:00.587137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4100fe73cb779382bacd53a54a28440d2adfb43","claim":"Entrada Therapeutics, Inc. reported the fourth quarter and full year ending December 31, 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022.","evidence_excerpt":"Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2022 and other corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/0001689375-23-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ending December 31, 2022"},{"label":"Net income","value":"Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}